A Study of valproic acid for patients with spinal muscular atrophy

Neurology and Clinical Neuroscience

Volumn 3, Issue 2, 2015, Pages 49-57

  Saito, Toshio ^a   Nurputra, Dian K ^b,c   Harahap, Nur Imma F ^b,c   Harahap, Indra Sari K ^b,c   Yamamoto, Hiroshi ^a   Muneshige, Emi ^a   Nishizono, Hiroaki ^a   Matsumura, Tsuyoshi ^a   Fujimura, Harutoshi ^a   Sakoda, Saburo ^a   Saito, Kayoko ^d   Nishio, Hisahide ^b  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GADJAH MADA UNIVERSITY   (Indonesia)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Modified Hammersmith Functional Motor Scale for SMA; Respiratory function; SMN; Spinal muscular atrophy; Valproic acid

Indexed keywords

CARNITINE; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ASSESSMENT OF HUMANS; BODY WEIGHT DISORDER; CHILD; CLINICAL ARTICLE; COUGH PEAK FLOW; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; ERUCTATION; FATIGUE; FEMALE; HUMAN; LUNG FUNCTION TEST; MALAISE; MALE; MAXIMUM INSUFFLATION CAPACITY; MENTAL DISEASE; MODIFIED HAMMERSMITH FUNCTIONAL MOTOR SCALE; MOTOR PERFORMANCE; PHYSIOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT PARAMETERS; SOMNOLENCE; SPINAL MUSCULAR ATROPHY; VITAL CAPACITY;

EID: 85061963401     PISSN: None     EISSN: 20494173     Source Type: Journal    
DOI: 10.1111/ncn3.140     Document Type: Article

References (25)

1. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch. Neurol. 2011; 68: 979-84.
2. Zerres K, Davies KE. 59th ENMC InternationalWorkshop:Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands. Neuromuscul. Disord. 1999; 9: 272-8.
3. Wang CH, Finkel RS, Bertini ES et al. Consensus statement for standard of care in spinal muscular atrophy. J. Child Neurol. 2007; 22: 1027-49.
4. Lefebvre S, Bürglen L, Reboullet S et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155-65.
5. Lefebvre S, Burlet P, Liu Q et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 1997; 16: 265-9.
6. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. 2000; 15: 228-37.
7. Monani UR, Lorson CL, Parsons DW et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999; 8: 1177-83.
8. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in theSMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 1999; 96: 6307-11.
9. Mailman MD, Heinz JW, Papp AC et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med. 2002; 4: 20-6.
10. Harada Y, Sutomo R, Sadewa AH et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J. Neurol. 2002; 249: 1211-9.
11. Brichta L, Hofmann Y, Hahnen E et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 2003; 12: 2481-9.
12. Sumner CJ, Huynh TN, Markowitz JA et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 2003; 54: 647-54.
13. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006; 67: 500-1.
14. Brichta L, Holker I, Haug K, Klockgether T, Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 2006; 59: 970-5.
15. Swoboda KJ, Scott CB, Reyna SP et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE 2009; 4: e5268.
16. Piepers S, Cobben JM, Sodaar P et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. J. Neurol. Neurosurg. Psychiatry 2011; 82: 850-2.
17. Swoboda KJ, Scott CB, Crawford TO et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 2010; 5: e12140.
18. Kissel JT, Scott CB, Reyna SP et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE 2011; 6: e21296.
19. Darbar IA, Plaggert PG, Resende MB, Zanoteli E, Reed UC. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol. 2011; 11: 36.
20. Kissel JT, Elsheikh B, King WM et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve 2014; 49: 187-92.
21. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul. Disord. 2006; 16: 417-26.
22. Harahap IS, Saito T, San LP et al. Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. Brain Dev. 2012; 34: 213-22.
23. Kang SW, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am. J. Phys. Med. Rehabil. 2000; 79: 222-7.
24. Finder JD, Birnkrant D, Carl J et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am. J. Respir. Crit. Care Med. 2004; 170: 456-65.
25. Sugai F, Yamamoto Y, Miyaguchi K et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004; 20: 3179-83.